Detalhe da pesquisa
1.
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients.
Blood
; 139(16): 2499-2511, 2022 04 21.
Artigo
Inglês
| MEDLINE | ID: mdl-34995350
2.
Central nervous system lymphomas-Assessment and treatment and prevention of central nervous system relapse.
Hematol Oncol
; 2023 Jun 29.
Artigo
Inglês
| MEDLINE | ID: mdl-37381737
3.
CNS prophylaxis for diffuse large B-cell lymphoma.
Lancet Oncol
; 23(9): e416-e426, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36055310
4.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Lancet
; 397(10277): 892-901, 2021 03 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33676628
5.
Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
Br J Haematol
; 192(6): 1049-1053, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-32677095
6.
Chimeric antigen receptor T-cell therapy for mantle cell lymphoma with central nervous system involvement: Progress, but not perfect.
Br J Haematol
; 203(5): 701-703, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37743427
7.
Integration of PET in DLBCL.
Semin Hematol
; 60(5): 291-304, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-38326144
8.
A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.
Leuk Lymphoma
; 64(2): 329-338, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36480811
9.
Characteristics and Outcomes of Older Patients With Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study.
Clin Lymphoma Myeloma Leuk
; 23(5): 370-378, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36804727
10.
Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma.
Blood Adv
; 7(16): 4576-4585, 2023 08 22.
Artigo
Inglês
| MEDLINE | ID: mdl-37307169
11.
High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.
J Clin Oncol
; 41(35): 5376-5387, 2023 Dec 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37797284
12.
New Directions for Mantle Cell Lymphoma in 2022.
Am Soc Clin Oncol Educ Book
; 42: 1-15, 2022 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-35561299
13.
Non-Covalent BTK Inhibitors-The New BTKids on the Block for B-Cell Malignancies.
J Pers Med
; 11(8)2021 Aug 03.
Artigo
Inglês
| MEDLINE | ID: mdl-34442408
14.
Event free survival at 12 months (EFS12) in stage 1 DLBCL - a reassuring milestone?
Leuk Lymphoma
; 61(11): 2542-2543, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32812823
15.
Refractory α/ß-Hepatosplenic T-cell Lymphoma With Secondary CNS Dissemination and Severe Morbidity Related to Intrathecal Chemotherapy: A Case Report and Literature Review.
Clin Lymphoma Myeloma Leuk
; 19(10): e564-e567, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31362868